Adma Biologics (ADMA) Stock Price, Quote & News

Company Profile

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute e...

Industry: Biotechnology

Sector: Healthcare

Phone: 201 478 5552

Fax: 201 478 5553

Website: www.admabiologics.com

Address:

465 State Route 17, Ramsey, United States

MoneyGroupLLC Oct. 25 at 8:30 PM

Enter: $ADMA Calls Strike Price: $16 Expiry Date: NOV 21 2025 Buy in Price: $1.50 - $1.95 Sell Price: $2.73 Profit : +82% (Turn every $1 into $1.82) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

Abraham_Nav Oct. 25 at 3:54 PM

$ADMA Adam S. Grossman, President and CEO of ADMA Biologics, INC. (NASDAQ:ADMA), sold 21,000 shares of common stock on October 24, 2025, at a price of $16.0, for a total of $336,000. The transaction comes as ADMA maintains a strong financial position, with InvestingPro data showing impressive revenue growth of 44% and a healthy current ratio of 5.3x. On the same day, Grossman also exercised options to acquire 15,000 shares of ADMA Biologics common stock at $5.4, for a total value of $81,000.

1 · Reply

biffermeister Oct. 25 at 2:57 PM

$ADMA as a trader i'm here to make money. i luckily sold the 15's for 90% gain and bailed on rebuying at close. we'll see what monday brings in the way of opportunity.

0 · Reply

biffermeister Oct. 25 at 2:34 PM

$ADMA somebody tell miss summer i apologize for being snarky.

0 · Reply

MitchOnX Oct. 25 at 1:20 PM

$ADMA $ADMA Adma Biologics Inc - 60 Second Analysis - October 25, 2025 #ADMA #... https://youtu.be/-Lo96OrCwEo?si=nYSR4qYLUiuUbGiT via @YouTube

1 · Reply

BabetteCH Oct. 25 at 11:16 AM

$ADMA https://www.marketbeat.com/instant-alerts/filing-first-citizens-bank-trust-co-buys-26752-shares-of-adma-biologics-inc-adma-2025-10-25/

0 · Reply

Numpsey Oct. 25 at 11:01 AM

$ADMA I think the shock of the stock price plunge, got everyone including myself in a panic .Now that the dust has settled cooler heads will prevail. I like to call it spillage like at a restaurant or bar dropping food or liquor or an assembly line where products get damaged and have to be tossed. this happens in all manufacturing. hopefully a one off. Stat frosty.✌️

1 · Reply

BabetteCH Oct. 25 at 8:54 AM

$ADMA Revenue Impact 2-2,5 Mio. USD - not much! I have spent several hours researching this topic in depth with the help of AI. The result:

1 · Reply

BabetteCH Oct. 25 at 6:54 AM

$ADMA I‘m still bullish. We‘ve seen stronger buying interest over the past few days. If we will see a slightly drop we have a tripple bottom! Back the issue: From a business model perspective, the current situation for ADMA Biologics appears to be more a part of normal operational risk than a serious cause for concern. ADMA operates in a highly regulated biological environment, where lot testing, voluntary withdrawals, and FDA safety communications occur regularly—especially with plasma-based therapies such as BIVIGAM or ASCENIV. Events like this are essentially part of ongoing pharmacovigilance and are typically priced in by the market only temporarily (if at all), as long as no systemic manufacturing issues or persistent quality problems emerge. However, a reassuring statement or brief PR from CEO Adam Grossman would be a smart move to demonstrate confidence and transparency and to avoid speculation—particularly since ASCENIV is a higher-margin, key product for the company

0 · Reply

FatLoads Oct. 25 at 3:28 AM

$ADMA makes no sense trending for this reason

1 · Reply

3 Biotech Stocks I Am Accumulating

HRMY INCY SNDX XBI

Sep 3, 2025, 6:12 AM EDT - 7 weeks ago

ADMA Biologics: Strong Product Mix, Growing Margins And Compelling Upside

Aug 10, 2025, 9:15 AM EDT - 2 months ago

ADMA Biologics: Optionality With SG-001 And A Vertically Integrated IG Platform

Aug 8, 2025, 3:58 PM EDT - 2 months ago

ADMA Biologics: A Better Quarter Than Headline Numbers

Aug 6, 2025, 9:14 PM EDT - 2 months ago

ADMA Biologics, Inc. (ADMA) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:05 PM EDT - 2 months ago

ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 7:00 AM EDT - 3 months ago

ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025

Jun 15, 2025, 4:11 AM EDT - 4 months ago

ADMA Biologics: Slowing Growth Warrants A Shift To Neutral (Rating Downgrade)

May 9, 2025, 3:54 AM EDT - 6 months ago

ADMA Biologics: Ready For More Growth Despite Q1 Earnings Miss

May 7, 2025, 11:05 PM EDT - 6 months ago

ADMA Biologics, Inc. (ADMA) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 6 months ago

ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update

Apr 30, 2025, 7:00 AM EDT - 6 months ago

ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025

Apr 28, 2025, 7:00 AM EDT - 6 months ago

ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process

Apr 7, 2025, 7:00 AM EDT - 7 months ago

ADMA Biologics Statement on Tariffs

Mar 21, 2025, 3:04 PM EDT - 7 months ago

ADMA Biologics: Premium Valuation Justified By Strong Fundamentals And Future Potential

Mar 4, 2025, 1:50 PM EST - 8 months ago

BREAKING: Block & Leviton Investigating ADMA Biologics, Inc. for Securities Fraud Violations Following Delayed 10-K and KPMG Evaluation of Controls

Mar 3, 2025, 6:24 PM EST - 8 months ago

ADMA Biologics, Inc. (ADMA) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 4:05 PM EST - 8 months ago

ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 28, 2025, 7:00 AM EST - 8 months ago

ADMA Biologics to Participate in the Raymond James Institutional Investor Conference

Feb 25, 2025, 7:00 AM EST - 8 months ago

ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Feb 6, 2025, 1:46 PM EST - 9 months ago

ADMA Biologics: Recent Pullback Is A Perfect Opportunity To Add

Dec 20, 2024, 7:00 AM EST - 11 months ago

ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility

Dec 13, 2024, 5:15 PM EST - 11 months ago

ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

Dec 11, 2024, 6:15 PM EST - 11 months ago

ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Dec 9, 2024, 5:45 PM EST - 11 months ago

ADMA Biologics, Inc. Is Being Investigated For Defrauding The Public And Affected Investors Are Invited To Contact The Schall Law Firm

Dec 7, 2024, 5:30 PM EST - 11 months ago

ADMA Biologics, Inc. Is Being Investigated For Fraud And Investors With Losses Are Invited To Reach Out To The Schall Law Firm

Dec 5, 2024, 2:15 PM EST - 11 months ago

ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Invited To Contact The Schall Law Firm

Dec 3, 2024, 3:15 PM EST - 11 months ago

ADMA Biologics, Inc. Is Being Looked Into For Securities Fraud And Investors With Losses Are Invited To Assist The Schall Law Firm

Dec 2, 2024, 8:30 AM EST - 11 months ago

ADMA Biologics: Capitalizing On A $20 Billion IG Market With ASCENIV

Dec 1, 2024, 3:15 PM EST - 11 months ago

ADMA Biologics, Inc. Is Being Investigated For Fraud And Impacted Investors Are Invited To Contact The Schall Law Firm

Nov 29, 2024, 12:30 PM EST - 11 months ago

ADMA Biologics, Inc. Is Being Investigated For Committing Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Nov 26, 2024, 11:00 AM EST - 11 months ago

ADMA Biologics, Inc. Is Being Investigated For Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

$The Schall Law Firm Wants Shareholders With Losses To Join An Inquiry Into ADMA Biologics Inc For Securities Related Infractions$

Nov 25, 2024, 1:00 PM EST - 11 months ago

The Schall Law Firm Wants Shareholders With Losses To Join An Inquiry Into ADMA Biologics Inc For Securities Related Infractions

Nov 24, 2024, 2:00 PM EST - 11 months ago

ADMA Biologics, Inc. Is Being Investigated For Engaging In Securities Fraud And Impacted Investors Are Urged To Contact The Schall Law Firm

Nov 20, 2024, 12:00 PM EST - 1 year ago

ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Invited To Help The Schall Law Firm

Nov 18, 2024, 12:45 PM EST - 1 year ago

ADMA Biologics, Inc. Is Being Investigated For Defrauding The Public And Affected Investors Are Urged To Contact The Schall Law Firm

MoneyGroupLLC Oct. 25 at 8:30 PM

0 · Reply

Abraham_Nav Oct. 25 at 3:54 PM

1 · Reply

biffermeister Oct. 25 at 2:57 PM

$ADMA as a trader i'm here to make money. i luckily sold the 15's for 90% gain and bailed on rebuying at close. we'll see what monday brings in the way of opportunity.

0 · Reply

biffermeister Oct. 25 at 2:34 PM

$ADMA somebody tell miss summer i apologize for being snarky.

0 · Reply

MitchOnX Oct. 25 at 1:20 PM

$ADMA $ADMA Adma Biologics Inc - 60 Second Analysis - October 25, 2025 #ADMA #... https://youtu.be/-Lo96OrCwEo?si=nYSR4qYLUiuUbGiT via @YouTube

1 · Reply

BabetteCH Oct. 25 at 11:16 AM

$ADMA https://www.marketbeat.com/instant-alerts/filing-first-citizens-bank-trust-co-buys-26752-shares-of-adma-biologics-inc-adma-2025-10-25/

0 · Reply

Numpsey Oct. 25 at 11:01 AM

1 · Reply

BabetteCH Oct. 25 at 8:54 AM

$ADMA Revenue Impact 2-2,5 Mio. USD - not much! I have spent several hours researching this topic in depth with the help of AI. The result:

1 · Reply

BabetteCH Oct. 25 at 6:54 AM

0 · Reply

FatLoads Oct. 25 at 3:28 AM

$ADMA makes no sense trending for this reason

1 · Reply

methasophales Oct. 25 at 2:28 AM

$ADMA Back in March ADMA voluntarily withdrew 3 lots of Bivigam and recorded a $3.8M dollar hit for credits on those lots. I'm sure they will voluntarily withdraw these two lots as well. 1-Bivigam and 1- asceniv. Impact of voluntarily withdrawing these two lots according to my estimates about $3.5M.

1 · Reply

Abraham_Nav Oct. 25 at 2:24 AM

$ADMA the Form 4 shows the sale was made under a pre-existing Rule 10b5-1 plan (Dec 5, 2024), which is a strong defense — and the public FDA safety notice is dated the same day (Oct 24, 2025). Here’s exactly what I checked and why that matters: 1. What the Form 4 shows (key facts). • Adam S. Grossman’s Form 4 lists the 10/24/2025 transactions (21,000 shares sold at $16). • The Form explicitly states the transactions were “pursuant to a Rule 10b5-1 trading plan entered into … on December 5, 2024.” • The Form is signed 10/24/2025.

0 · Reply

BryanRobinson Oct. 25 at 2:17 AM

$ADMA

0 · Reply

justusfied Oct. 25 at 2:15 AM

$ADMA thank you @BrookeSummer for your informed and intelligent analysis of the current situation.

0 · Reply

Tradeswithyourmom Oct. 25 at 2:11 AM

$ADMA So it was 2 of our lots and 4 Grifols lots. Look at their share price today, it barely moved. If this was a huge event I would've expected a selloff on both stocks. Do you think it's possible someone shorted a bunch of ADMA to try to get cheaper shares in a desirable company?

0 · Reply

BrookeSummer Oct. 25 at 1:51 AM

$ADMA I am leaning more that this is a donor-site specific proteins or something that has nothing to do with their manufacturing process due to ADMAs massive distribution growth that happened in 2024-2025. They now have access to over 200 infusion centers on top of the ten they own. This most likely stays a safety field event and at most leads to a voluntary withdrawal like before. I am going to add on dips, if it dips more. If you cannot afford to lose then set stop losses and if that hits add back when it makes sense. I trust Adam on this and it will probably be quietly rolled up into earnings like last time if any withdrawals or earnings revisions are needed.

2 · Reply

Two_Cents_Worth Oct. 25 at 1:35 AM

$ADMA According to my TradingView page, Adam sold 21,000 shares of common stock on October 24, at a price of $16.00. Will he get in trouble if he knew the bad news before he sold??

1 · Reply

Two_Cents_Worth Oct. 25 at 1:27 AM

$ADMA After over a year being out of this and then I start scaling back in just before bad news hits. My timing is impeccably bad. Lets hope it's not that bad

1 · Reply

bhcapital Oct. 25 at 12:42 AM

$IOVA will be the next $ADMA in a 2-3 timeframe cycle.

1 · Reply

Hipoppier Oct. 25 at 12:03 AM

$ADMA that $16 dump today reminded me when this was at $20 and just fell right off da cliff

1 · Reply

BrookeSummer Oct. 25 at 12:02 AM

$ADMA For the q1 event the hit to revenue was $3.8M and the fda lists 3 bivigam lots impacted (jan, feb, mar one each). I need to look at actual earnings filing to see if they voluntarily withdrew 2 or 3 of those listed. This time its still investigational, and any guidance is precautionary and no telling if the more severe reactions were in grifols or in both. This time there is one asceniv and 1 bivigam. Asceniv has higher margin and is most likely the sell off reaction. This could be just another volunatary recall. But bivigam hit to revenue will be small, perhaps less than 1.5/2M and depending on asceniv revenue per one lot would be total revenue impact if they should have to withdraw the lots.

1 · Reply

MCMI Oct. 25 at 12:02 AM

$ADMA you can always sell and buy lower. Or you can sell lower and buy higher. Up to you.

1 · Reply

Market Cap	3.64B
Revenue (ttm)	426.45M
Net Income (ttm)	197.67M
EPS (ttm)	N/A
PE Ratio	26.14
Forward PE	24.06
Profit Margin	46.35%
Debt to Equity Ratio	0.18

Volume	5,567,300
Avg Vol	3,252,390
Day's Range	N/A - N/A
Shares Out	238.63M
Stochastic %K	54%
Beta	0.47
Analysts	Strong Sell
Price Target	$30.67